The present invention relates to the use of nucleoside derivatives of
formula I
##STR1##
wherein B signifies a 9-purinyl residue B1 of formula
##STR2##
or a 1-pyrimidyl residue B2 of formula
##STR3##
wherein the symbols are as defined in the specification,
and of pharmaceutically acceptable salts thereof; for the treatment of
diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a
medicament for such treatment and to pharmaceutical compositions
containing such compounds.
